CCL20 and neoplasm: These results indicate that intratumoral treatment of TC-1 tumors with NP(dox+pIC+R848+MIP3α) enhances the lymphoid cell populations in the tumor but not in the spleen, and does not alter the myeloid population within the tumor microenvironment.